Minnesota health maintenance organizations increased their average per-member premium revenue but continued to lose money, according to the recently released Minnesota Managed Care Review 1999.
Minnesota health maintenance organizations increased their average per-member premium revenue but continued to lose money, according to the recently released Minnesota Managed Care Review 1999. The review, the tenth annual report assessing the Minnesota health care market, is a competitive analysis of health plans in the state.
The study found that:
•Â HMOs' premium revenues for commercial (employer) plans increased by an average of 9.9%.
•Â Despite those increases, Minnesota HMOs lost $9.6 million, or 0.3% of $2.9 billion in revenues in 1998.
•Â HMOs increased profits on their Medicaid plans from $25.9 million in 1997 to $33.8 million in 1998.
•Â Enrollment in insured HMO plans declined by about 45,000 in 1998.
According to Allan Baumgarten, the independent research analyst and health care policy and finance consultant who authored the report, the findings of the study may also reveal national trends. "In Minnesota and a number of other markets, we're seeing some large employer groups going not from preferred provider organizations to HMOs, which was sort of the conventional wisdom, but, in fact, going the opposite direction â from HMOs back to PPOs, something more lightly managed," he said.
To counter the loss of membership that this employer-driven shift would bring, Baumgarten said HMOs will start diversifying into other products: "You'll see more HMOs wanting to perhaps add these lines of business â PPOs and other more lightly managed care â so if they have unhappy customers, they can say, 'Wait a minute, we have other products in our line⦠that maybe address some of your concerns.'"
The problem with this diversification, however, is that HMOs may not have the right skill sets to offer other types of managed care products. "That might be one of the factors that distinguishes the companies that are going to be successful⦠and [the ones] that are going to have serious problems," Baumgarten said.
The results of the study reveal a cloudy horizon for HMOs. "HMOs are still under a lot of pressure both on the profitability, premium and medical cost side," Baumgarten said. "Plus, customers are raising questions about the value they get from their HMOs. It all adds up to a very challenging time for HMOs." PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.